MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer

S Roy1, E Kenny, S Kennedy

  • 1St. Vincent's University Hospital, Dublin 4, Ireland.

Anticancer Research
|June 28, 2007
PubMed
Abstract

Insights

Drug efflux pumps, MDR1 and MRP-1, are frequently expressed in non-small cell lung cancer (NSCLC). Further research is needed to understand their role in multiple drug resistance (MDR) in NSCLC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Multiple drug resistance (MDR) poses a significant challenge in treating non-small cell lung carcinomas (NSCLC).
  • Drug efflux pumps, such as MDR1 and MRP-1, are implicated in conferring MDR in various cancers.

Purpose of the Study:

  • To investigate the prevalence of MDR1 and MRP-1 gene and protein expression in NSCLC.
  • To determine the relative expression levels of these drug efflux pumps at both mRNA and protein levels.

Main Methods:

  • Analysis of 38 NSCLC tumor specimens using immunohistochemistry.
  • Reverse-transcription polymerase chain reaction (RT-PCR) was performed on 30 of these specimens.

Main Results:

  • Both MDR1 and MRP-1 drug efflux pumps were frequently expressed in NSCLC.
  • MRP-1 mRNA expression was more prevalent than MDR1 mRNA.
  • MDR1 P-glycoprotein (P-gp) protein was detected more frequently than MRP-1 protein.
  • Discrepancies between mRNA and protein detection suggest potential differences in assay sensitivity.

Conclusions:

  • Drug efflux pumps MDR1 and MRP-1 are commonly expressed in NSCLC, contributing to multiple drug resistance.
  • Further investigation using sensitive qPCR and protein analysis in larger cohorts is warranted to clarify their precise role in NSCLC MDR.